Sarepta names Art Krieg as CSO


Dr. Krieg joins Sarepta (SRPT) from RaNA Therapeutics where he was CEO since co-founding the company in 2011. Prior to that, he was CSO of Pfizer's Oligonucleotide Therapeutics Unit from 2008-11.

Krieg: "The recent resurgence in the field of RNA therapeutics has been due in part to the excitement around Sarepta’s exon skipping therapies and their potential for patients with Duchenne."

Shares -1.6% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs